zapnometinib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 24, 2019 (NCT04385420)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl- Mol. weight
- 409.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL481949 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05555823 | Phase 1 | Jun 23, 2022 | Atriva Therapeutics GmbH |
| NCT04776044 | Phase 2 | Apr 12, 2021 | Atriva Therapeutics GmbH |
| NCT04385420 | Phase 1 | Apr 24, 2019 | Atriva Therapeutics GmbH, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atriva Therapeutics GmbH | For profit | 3 | 3 | 2 | 2019 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1